NCT00430807

Hydroxychloroquine in Giant Cell Arteritis

Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: University Hospital, Toulouse · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Cortico-dependence is frequent in giant cell arteritis patients, and no drugs has proved its ability to prevent corticodependence. Hydrocychloroquine is a well tolerated immunomodulatory drug that may have a corticosteroid sparing potential according to immuno-pharmacological and clinical data. We have designed a multcentric double blind versus placebo randomized controled trial to assess the corticosteroid sparing effect of hydroxychloroquine in non complicated giant cell arteritis.

Conditions

• Giant Cell Arteritis

Interventions

Type	Name	Description
DRUG	hydroxychloroquine/placebo

Timeline

• Start date: 2002-01-01
• Primary completion: 2005-01-01
• Completion: 2006-12-01
• First posted: 2007-02-02
• Last updated: 2015-10-06

Locations

23 sites across 1 country: France